FDA to Decide on New Lung Cancer Treatment in November
The pending decision could offer a new therapy for patients whose EGFR-mutated lung cancer has progressed.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Is it better to start available treatments now rather than waiting for potential new drug approvals?
On November 14, 2026, the FDA is scheduled to reach a decision on whether to approve ivonescimab for use with chemotherapy. The treatment is intended for patients with EGFR-mutated lung cancer who have previously seen their disease progress after standard targeted therapies.
Why it matters
This review represents a potential shift for patients who have exhausted initial lines of targeted treatment for EGFR-mutated lung cancer. The FDA evaluation process will weigh the clinical evidence for this combination against existing treatment standards to determine if it is ready for broader use in the United States.
In the HARMONi trial, which enrolled 438 patients, the combination therapy reached a median progression-free survival of 6.8 months compared to 4.4 months for chemotherapy alone. Grade 3 or higher side effects were reported in 50.0% of the treatment group versus 42.2% for those receiving chemotherapy alone.
The players
FDA
The federal agency responsible for protecting public health by regulating pharmaceuticals and medical devices.
AstraZeneca
A global pharmaceutical company that invests in oncology treatments and recently acquired a 12% stake in Summit Therapeutics.
Summit Therapeutics
A biopharmaceutical company developing novel therapies for cancer patients.
The details
Ivonescimab functions as a bispecific antibody that simultaneously blocks PD-1 and VEGF pathways to inhibit tumor growth. This dual-action approach aims to both stimulate the immune system to target cancer cells and reduce the blood supply supporting the tumor. The medication is administered as an intravenous infusion to patients in a clinical setting.
Timeline
May 2024: Chinese regulators approved ivonescimab for patient use.
January 2026: The FDA accepted the application for ivonescimab.
June 2026: Data cutoff for updated HARMONi survival analysis.
September 28, 2026: Summit Therapeutics announced an equity investment from AstraZeneca.
November 14, 2026: The FDA is expected to reach a final decision on approval.
Health Landscape
The potential approval of ivonescimab follows the HARMONi global trial, which serves as the primary clinical evidence for this regulatory evaluation. This development sits alongside ongoing efforts to improve outcomes for EGFR-mutated lung cancer patients who have seen their disease progress after third-generation targeted pill treatment.
Patients with EGFR-mutated lung cancer should discuss their current treatment trajectory and future options with their oncology care team ahead of this pending decision. It is important to review the specific side-effect profile of this combination, including severe VEGF-related risks, when evaluating potential therapy changes.
The takeaway
The upcoming FDA decision will determine if a new dual-action therapy becomes available for patients with specific forms of lung cancer. Patients should track this regulatory update and consult with their physician about how these findings relate to their personal treatment plan.
What happens next
The FDA will release its final decision on the approval of ivonescimab on November 14, 2026.
Further reading
For more information on current treatment landscapes, explore our resources on Cancer.
More information
To review registered research studies, search clinical trials for ivonescimab.
Source note: This article includes information reported by Medical Daily.
Live Poll
Is it better to start available treatments now rather than waiting for potential new drug approvals?
